A real breakthrough for PDAC patients - Ras-targeted therapies are actually here
Helen Matthews
There hasn't previously been a treatment vs pancreatic cancer this successful. Striking improved (a doubling) survival results
@nejm.org and @ascocancer.bsky.social published
today with daraxonrasib, which also became available via an FDA-approved early access program
nejm.org/doi/full/10....
